New Clinical Trials at Texas Retina
Over the past two decades, Texas Retina physicians have participated in more than 100 national clinical trials, offering our patients access to promising new treatments for a variety of retina conditions, including
read more
New Treatments Available for Geographic Atrophy
We know geographic atrophy (GA) can negatively impact patients’ quality of life and independence. While it still cannot be cured, Texas Retina is excited to finally have two new GA treatment options
read more FDA Approves First Treatment for Geographic Atrophy
On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved intravitreal pegcetacoplan (brand name Syfovre), the first-ever treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Texas Retina
read more
What is Geographic Atrophy?
Approximately 20% of patients with age-related macular degeneration (AMD) will develop a condition called geographic atrophy (GA). It is considered a late stage of AMD and involves chronic, progressive degeneration of regions
read more
New Clinical Trials Offer Patients Access to Promising New Retina Treatments
At Texas Retina Associates, we remain committed to safely providing our patients with compassionate and personalized retina care, including access to breakthrough, sight-saving treatments through clinical trials. In fact, our physicians have
read more